Description
The marker is associated with the peculiarities of drug metabolism in the liver. It is examined to identify the physiological efficacy of using drugs of the following groups: antiplatelet agents (clopidogrel and its analogues), proton pump inhibitors (omeprazole, lansoprazole), antifungals (voriconazole), antidepressants, etc.
Alternative designation of the genetic marker CYP2C19*17.
Period of execution
Within 8 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Buccal (cheek) epithelium
- Venous blood